SEC I	Form 4
-------	--------

Instruction 1(b)

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OVAL
OMB Number:	3235-0287
Estimated average bur	den
hours per response:	0.5

Īr

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC /	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
BOGER JOSHUA S	MA [ VRTX ]	X Director 10% Owner				
(Last) (First) (Middle)		X Officer (give title Other (specify below)				
C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET	3. Date of Earliest Transaction (Month/Day/Year) 11/14/2006	President & CEO				
150 WAVERLY SIREEI	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)		X Form filed by One Reporting Person				
CAMBRIDGE MA 02139		Form filed by More than One Reporting Person				
(City) (State) (Zip)						

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	11/14/2006		М		11,000	A	\$15.56	1,046,403	D	
Common Stock	11/14/2006		<b>S</b> <sup>(1)</sup>		11,000	D	\$42.37	1,035,403	D	
Common Stock								207,500	I	shares in trust <sup>(2)</sup>
Common Stock					1			15,979	I	401(k)

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(0.9., parte, carrel, control and coordinate)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$15.56	11/14/2006		М			11,000	03/12/1997 <sup>(3)</sup>	12/11/2006	Common Stock	11,000	\$0	2,004,531	D	

**Explanation of Responses:** 

1. Transaction made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.

2. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.

3. Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/12/1996.

**Remarks:** 

Valerie L. Andrews, Attorney-

In-Fact

11/15/2006

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.